347 related articles for article (PubMed ID: 19932513)
1. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
2. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
[TBL] [Abstract][Full Text] [Related]
4. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
[TBL] [Abstract][Full Text] [Related]
6. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
9. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
[TBL] [Abstract][Full Text] [Related]
10. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
[TBL] [Abstract][Full Text] [Related]
11. CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis.
McKay FC; Swain LI; Schibeci SD; Rubio JP; Kilpatrick TJ; Heard RN; Stewart GJ; Booth DR
J Autoimmun; 2008 Aug; 31(1):52-8. PubMed ID: 18406576
[TBL] [Abstract][Full Text] [Related]
12. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
13. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease.
Biagi E; Di Biaso I; Leoni V; Gaipa G; Rossi V; Bugarin C; Renoldi G; Parma M; Balduzzi A; Perseghin P; Biondi A
Transplantation; 2007 Jul; 84(1):31-9. PubMed ID: 17627234
[TBL] [Abstract][Full Text] [Related]
14. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis.
Vandenbark AA; Huan J; Agotsch M; La Tocha D; Goelz S; Offner H; Lanker S; Bourdette D
J Neuroimmunol; 2009 Oct; 215(1-2):125-8. PubMed ID: 19758707
[TBL] [Abstract][Full Text] [Related]
15. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
[TBL] [Abstract][Full Text] [Related]
16. A possible role of CD4+CD25+ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis.
Xu G; Mou Z; Jiang H; Cheng L; Shi J; Xu R; Oh Y; Li H
Laryngoscope; 2007 May; 117(5):876-80. PubMed ID: 17473687
[TBL] [Abstract][Full Text] [Related]
17. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.
Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP
Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197
[TBL] [Abstract][Full Text] [Related]
18. Reduced production of noggin by immune cells of patients with relapsing-remitting multiple sclerosis.
Urshansky N; Mausner-Fainberg K; Auriel E; Regev K; Bornstein NM; Karni A
J Neuroimmunol; 2011 Mar; 232(1-2):171-8. PubMed ID: 21111488
[TBL] [Abstract][Full Text] [Related]
19. IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis.
Chen M; Chen G; Deng S; Liu X; Hutton GJ; Hong J
J Neuroimmunol; 2012 Jan; 242(1-2):39-46. PubMed ID: 22112394
[TBL] [Abstract][Full Text] [Related]
20. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
